According to the latest report by IMARC Group, titled, “Retinoblastoma Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global retinoblastoma treatment market size reached US$ 2.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.5 Billion by 2028, exhibiting a growth rate (CAGR) of 4.2% during 2023-2028.
Retinoblastoma represents one of the most common cancers that usually develops before the age of 5 in children. Some of the symptoms include a white appearance in the pupil, also called a cat’s eye reflex or leukocoria. Retinoblastoma treatment comprises a wide array of drug delivery and chemotherapy techniques that offer some benefits in the short term, as retinoblastoma is curable at the initial stage. Following the first or second chemotherapy cycle, several focal treatments can then be applied depending on how much the tumor shrinks and where it is in the eye. Surgery is the permanent retinoblastoma treatment option, as it removes the tumor thoroughly from the retina. There are various imaging tests available for a detailed diagnosis of retinoblastoma, such as ultrasound, CT scan, MRI, X-ray, bone scan, etc.
Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/retinoblastoma-treatment-market/requestsample
Retinoblastoma Treatment Market Trends and Drivers:
The increasing healthcare expenditure capacities for ophthalmic treatment procedures are primarily driving the retinoblastoma treatment market. Additionally, the rising investments in R&D activities for focusing on newer and more efficient therapeutic strategies with lesser associated side effects are further catalyzing the market growth. Besides this, the growing number of product approvals leading to the development of new drug variants is acting as another significant growth-inducing factor. Moreover, the widespread adoption of organic growth strategies undertaken by key market payers, such as strategic partnerships and collaborations, and mergers and acquisitions (M&As), is also positively influencing the global market. Apart from this, continuous improvements in medical infrastructures and the introduction of advanced technologies in clinical trials are anticipated to fuel the retinoblastoma treatment market over the forecasted period.
The competitive landscape of the industry has also been examined along with the profiles of the key players.
- Bristol Myers Squibb Company
- Pfizer Inc.
- Teva Canada Limited (Teva Pharmaceutical Industries Ltd.)
Ask Analyst for 10% Free Customized Report: https://www.imarcgroup.com/request?type=report&id=6732&flag=C
Retinoblastoma Treatment Market Report2023-2028 Competitive Analysis and Segmentation:
The report has segmented the market based on type, treatment type, type of staging, and application.
- Non-Hereditary Retinoblastoma
- Hereditary Retinoblastoma
Treatment Type Insights:
- Radiation Therapy
- Laser Therapy (Photocoagulation)
- Opthalmic Artery Infusion Chemotherapy
- High-Dose Chemotherapy and Stem Cell Transplant
Type of Staging Insights:
- Intraocular Retinoblastoma
- Extraocular Retinoblastoma
- Cancer Institutes
Breakup by Region:
- North America
- Latin America
- Middle East and Africa
Related Reports By IMARC Group
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800